Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022
Format: 13 videos + 16 pdfs, size: 3.02 GB
Course Audience: internist, family medicine physician, cardiologist, primary care physician
Overview:
Date & LocationFriday, September 30, 2022, 7:45 AM – 2:00 PM, Virtual, Philadelphia, PA
Course OverviewCVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.
Target AudienceSpecialties – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINELearning ObjectivesAfter completing this activity, participants should be able to:
- Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
- Identify appropriate blood pressure goals and management in several special patient populations
- Review the controversies regarding the appropriate treatment of and management of pregnant patients at risk for CVD.
- Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia in young patients.
- Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention
BP Goals and Use of Thiazides in Advanced CKD (Video MP4 Format)
BP Goals and Use of Thiazides in Advanced CKD (PDF Format)BP Goals Management in Elderly (STEP Trial and SPRINT) (Video MP4 Format)BP Goals Management in Elderly (STEP Trial and SPRINT) (PDF Format)BP22_Brochure_v4 (PDF Format)Cholesterol (Video MP4 Format)Cholesterol (PDF Format)Clinical Case Discussion FOUNDATIONS- REFRESHER OF THE CURRENT GUIDELINES (PDF Format)Clinical Case Discussion SPECIAL POPULATIONS (PDF Format)DM Weight loss (Video MP4 Format)DM Weight loss (PDF Format)Hypertension (Video MP4 Format)Hypertension (PDF Format)Lipid Management and Risk Assessment in Younger Patients (Video MP4 Format)Lipid Management and Risk Assessment in Younger Patients (PDF Format)New Agents in Lipid Management (Video MP4 Format)New Agents in Lipid Management (PDF Format)Non-steroidal MRAs in HTN, DM2, and CKD (Video MP4 Format)Non-steroidal MRAs in HTN, DM2, and CKD (PDF Format)Peripartum CV Risk Reduction (Video MP4 Format)Peripartum CV Risk Reduction (PDF Format)Polypill – Quad Study Combo Therapy for BP and Lipids (Video MP4 Format)Polypill – Quad Study Combo Therapy for BP and Lipids (PDF Format)Population-Wide Effects and Local Public Health Efforts of Sodium Reduction (Video MP4 Format)Population-Wide Effects and Local Public Health Efforts of Sodium Reduction (PDF Format)Update in Renal Denervation (Video MP4 Format)Update in Renal Denervation (PDF Format)Weight Loss Strategies in Highly Comorbid Patients (Video MP4 Format)Weight Loss Strategies in Highly Comorbid Patients (PDF Format)